ionctura Archives

Opinion 1 Nov 2023

Could this be the start of a new era for PI3K drugs?

There is hope that a rich biotech pipeline will produce a second generation of PI3K drugs after issues with the first generation from the class had brought up concerns. Phosphoinositide 3-kinases (PI3K) drugs work by inhibiting a pathway that plays a role in cell metabolism, growth, proliferation and survival that has become dysregulated in almost […]

November 1, 2023 - 7 minutesmins - By External Contributor

Best in Biotech 28 Feb 2023

5 advancements in rare disease research over the past year

There are more than 7,000 rare diseases that affect hundreds of millions of people worldwide. As Rare Disease Day is observed on February 28, here are five recent advancements that have transformed research and boosted the scope for the development of novel therapies. FDA approves tissue-agnostic therapies for rare cancers Tissue-agnostic drug development has been […]

February 28, 2023 - 6 minutesmins - By Roohi Mariam Peter

Best in Biotech 28 Feb 2023

10 biotech companies making a difference in rare diseases

February 28 is Rare Disease Day, which looks to raise awareness of rare diseases and bring about change for patients and families living with them. The event also brings attention to the need for improved access to diagnosis, as well as the need to develop more treatments to tackle a broader range of diseases. There […]

February 28, 2023 - 11 minutesmins - By Willow Shah-Neville

In Depth 1 Feb 2023

Cancer: what are the barriers to research?

Everyone imagines a world without cancer, but getting there is difficult. With World Cancer Day coming up on February 4, we took the opportunity to ask some life science company CEOs, CMOs, and chief scientific officers the same question about cancer research. We asked CellCentric CEO, Will West; iOnctura CEO, Catherine Pickering; ISA Pharmaceuticals chief […]

February 1, 2023 - 6 minutesmins - By Jim Cornall

In Depth 1 Feb 2023

How can cancer care be improved?

Labiotech recently asked several biotech experts the same question about tackling cancer, for a special newsletter to commemorate World Cancer Day on February 4. The 2023 theme is Close the Care Gap. The question, what are the biggest opportunities to improve cancer care, brought responses from Versameb CEO, Klaas Zuideveld; ImaginAb CEO, Ian Wilson; ISA […]

February 1, 2023 - 7 minutesmins - By Jim Cornall

News and Trends 20 Dec 2022

iOnctura raises €17.5M for pancreatic cancer therapy

iOnctura BV, a clinical-stage biotech developing novel cancer therapies, has been granted €17.5 million ($18.6 million) funding from the European Investment Council’s (EIC) accelerator program to develop IOA-289 for pancreatic cancer. The EIC’s funding consists of a grant of €2.5 million ($2.7 million), and €15 million ($16 million) of equity investment. Earlier this month, iOnctura […]

December 20, 2022 - 2 minutesmins - By Jim Cornall

brain cancer glioblastoma divide and conquer

News and Trends 23 Jan 2020

Merck Spinout Bags €15M Series A to Tackle Cancer and Fibrosis

iOnctura, a spinout from Merck KGaA, has raised €15M to take its cancer and fibrosis drugs to phase I clinical trials. The Series A round was co-led by new investors INKEF Capital and VI Partners. The founding investor of iOnctura, M Ventures — the corporate venture arm of Merck — also contributed to the round, […]

January 23, 2020 - 2 minutesmins - By Jonathan Smith

Best in Biotech 3 Dec 2019

Industry Perspectives: Women in Biotech 2019

Women are underrepresented in biotech leadership roles in Europe, but things are slowly improving. We spoke to five senior women from the industry who told us their stories. At least half of life sciences and medical students across Europe are women. In the biotech and pharma industry, this statistic is similar in entry level jobs, […]

December 3, 2019 - 5 minutesmins - By Helen Albert

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us